Juvenile Arthritis News

Janus kinase inhibitors “may prove useful” in a wider range of immune-mediated inflammatory diseases, including refractory cutaneous dermatomyositis, chronic plaque psoriasis and other conditions, according to a speaker here.

Given the link between puberty and autoimmune rheumatic disease, a group of researchers has recommended that clinical assessments of young patients with such conditions record pubertal issues at every encounter.

During the early months of the COVID-19 pandemic, increased all-cause mortality in patients with rheumatoid arthritis and other inflammatory joint diseases largely mirrored that of the general population, according to data.

Subcutaneous tocilizumab provides similar exposure and risk-benefit profiles as intravenous tocilizumab in patients with systemic juvenile idiopathic arthritis, according to findings published in Rheumatology.

Patients’ response to anti-CTLA-4 or anti-PD-1 checkpoint therapy for advanced melanoma, and their incidence of immune-related adverse events of grade 3 or higher, were similar regardless of preexisting autoimmune disease, according to data.

A subset of patients with systemic juvenile idiopathic arthritis with elevated interleukin-18 markers could face “increased risk” for macrophage activation syndrome, according to a speaker at the Basic and Clinical Immunology for the Busy Clinician symposium.

Uveitis has a “significant impact” on visual functioning and vision-related quality of life among children with juvenile idiopathic arthritis, according to data published in Arthritis Care & Research.

Undeterred by the FDA’s rejection of filgotinib over testicular toxicity concerns, the United Kingdom’s National Institute for Health and Clinical Excellence has endorsed its use among eligible patients on England’s National Health Service.

Emerging research suggests a link between chronic stress and the development of arthritis, including rheumatoid arthritis, according to a review published in Arthritis Care & Research.

A stepwise approach to immunomodulatory drugs is recommended for children with multisystem inflammatory syndrome linked to COVID-19, with IVIG and glucocorticoids as first-tier agents, noted updated American College of Rheumatology guidance.